肠道微生物群与非酒精性脂肪性肝病的最新研究进展

Recent advances in gut microbiota and non-alcoholic fatty liver disease

非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)是近年来世界上最常见的肝病之一,是一种多因素疾病,包括生活方式、环境、饮食习惯、遗传易感性、代谢综合征和肠道微生物群失调等。多项研究报道肠道微生物群在NAFLD的发生、发展中作用重大,主要通过肠-肝轴、肠道微生物成分和微生物代谢产物的异常调节影响胆汁酸的分泌,从而促进NAFLD的发生、发展,因此,被认为是NAFLD的药理学和临床治疗的潜在靶点。现对近几年以肠道微生物群为基础治疗NAFLD的最新方法进行总结,对肠道微生物群的主要特点、其与NAFLD的相关性研究、可能作用机制作一概述。

Non-alcoholic fatty liver disease(NAFLD)is one of the most common chronic liver diseases in the world.It is a multifactorial disease including lifestyle,environment,eating habits,genetic susceptibility,metabolic syndrome and gut microbiota.A number of experimental studies have reported that intestinal microbiota dysfunction plays an important role in the development of NAFLD.The gut microbiota contributes to NAFLD by abnormal regulation of the gutliver axis,gut microbial components and microbial metabolites,and affects the secretion of bile acids.Due to the key role of the gut microbiota in NAFLD,it has been regarded as a potential target for the pharmacological and clinical treatment of NAFLD.This review summarized the characterization of gut microbiota and the significant association between the gut microbiota and NAFLD.The potential therapeutic methods for NAFLD based on the gut microbiota,the possible mechanisms of how the gut microbiota are involved in promoting the development,and progression of NAFLD were summarized in this article.